<DOC>
	<DOCNO>NCT01926015</DOCNO>
	<brief_summary>The study evaluate immunogenicity Diphtheria , Tetanus , Pertussis Inactivated Poliovirus Vaccine ( DTP-IPV ) concomitant administration RotaTeq™ ( V260 ) healthy Japanese infant . The hypothesis test antibody response rate DTP-IPV concomitant administration RotaTeq™ non-inferior stagger administration RotaTeq™ .</brief_summary>
	<brief_title>Immunogenicity Safety Concomitant Administration RotaTeq™ ( V260 ) Diphtheria , Tetanus , Pertussis Inactivated Poliovirus Vaccine ( DTP-IPV ) Healthy Japanese Infants ( V260-060 )</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Japanese participant Age 6 week &lt; 11 week ( 42 76 day date birth ) Visit 1 History hypersensitivity and/or anaphylaxis product ingredient V260 DTPIPV Gastrointestinal disorder , growth retardation , failure thrive History intussusception Untreated congenital gastrointestinal disorder ( Meckel diverticulum ) Known suspect impairment immunological function , include severe immunodeficiency ( SCID ) Cardiovascular , renal , liver , blood disease History convulsion Undergoing immunosuppressive therapy live close relative congenital immune deficiency Prior vaccination rotavirus vaccine and/or DTPIPV vaccine Live vaccine receive within 28 day inactivate vaccine receive within 7 day At high risk tuberculosis exposure</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>11 Weeks</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>